RESUMO
In this case series, we report for the first time in the literature in a cohort, the positive response to oral or topical antifungals for atopic dermatitis patients treated with Dupilumab that developed Dupilumab facial redness, supporting the Malassezia hypersensitivity theory.
Assuntos
Dermatite Atópica , Eczema , Anticorpos Monoclonais Humanizados/efeitos adversos , Dermatite Atópica/induzido quimicamente , Dermatite Atópica/tratamento farmacológico , Eritema/induzido quimicamente , HumanosAssuntos
Anticorpos Monoclonais Humanizados/administração & dosagem , COVID-19/imunologia , Dermatite Atópica/tratamento farmacológico , Fármacos Dermatológicos/administração & dosagem , SARS-CoV-2/imunologia , Anticorpos Monoclonais Humanizados/efeitos adversos , COVID-19/diagnóstico , COVID-19/virologia , Dermatite Atópica/diagnóstico , Dermatite Atópica/imunologia , Fármacos Dermatológicos/efeitos adversos , Esquema de Medicação , Interações Hospedeiro-Patógeno , Humanos , Hospedeiro Imunocomprometido , Masculino , Medição de Risco , Resultado do Tratamento , Adulto JovemRESUMO
Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) are endemic diseases in America, especially in some countries such as Colombia. Among the therapeutic options is amphotericin B (AB). Nevertheless, its lipid-associated formulations have better safety profiles and effectiveness in other diseases, so far with no comparative studies in CL or MCL. We conducted a retrospective descriptive study describing the effectiveness and adverse effects of AB deoxycholate (ABD), AB colloidal dispersion (ABCD), and liposomal AB (LAB) as third-line treatments for CL and MCL. The effectiveness of LAB (88.5%) was greater than those of ABCD (66.6%) and ABD (80.8%). There were also fewer adverse effects in the LAB group (46.2%) than in the ABD (96.1%) and ABCD (80.9%) groups. LAB is an alternative for the treatment of CL and MCL in patients with therapeutic failure to first- and second-line drugs; findings suggest it might be less toxic and more effective than ABD and ABCD.
Assuntos
Anfotericina B/efeitos adversos , Anfotericina B/uso terapêutico , Ácido Desoxicólico/uso terapêutico , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Mucocutânea/tratamento farmacológico , Antiprotozoários/efeitos adversos , Antiprotozoários/uso terapêutico , Coloides , Colômbia/epidemiologia , Ácido Desoxicólico/efeitos adversos , Combinação de Medicamentos , Humanos , Leishmaniose Cutânea/epidemiologia , Leishmaniose Mucocutânea/epidemiologia , Estudos RetrospectivosRESUMO
El libro resalta que la lepra continúa siendo una enfermedad presente en Colombia y que aún constituye un problema de salud pública importante por los costos sociales, económicos y de sufrimiento humano que conlleva. Sabiendo que la literatura sobre el tema es escasa en nuestro medio, este libro surge como una herramienta de consulta creada para médicos y otros profesionales de salud, con la certeza de que es preciso mejorar la oportunidad del diagnóstico. Siendo fundamental que, durante su proceso formativo, todos los profesionales de la salud adquieran conocimientos sobre dicha enfermedad, que cada día se hace más visible por sus secuelas y diagnóstico tardío.
The book highlights the fact that leprosy continues to be a disease present in Colombia and that it is still a major public health problem due to the social, economic and human suffering costs it entails. Knowing that the literature on the subject is scarce in our country, this book is intended as a reference tool for doctors and other health professionals, in the knowledge that it is necessary to improve the timeliness of diagnosis. It is essential that, during their training process, all health professionals acquire knowledge about this disease, which is becoming more and more visible every day due to its sequelae and late diagnosis.